[{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"MedinCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell\u2019s Partner Teva Provides Additional Information Regarding the New Drug Application for mdc-IRM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO\u00ae (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington\u2019s Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Assia Chemical Industries Ltd
AUSTEDO (deutetrabenazine) is the first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia (TD) in adults and for the treatment of chorea associated with Huntington’s disease.
mdc-IRM, (risperidone) extended-release injectable suspension for the treatment of patients with schizophrenia (Teva codename: TV-46000), is the most advanced investigational product based on MedinCell’s BEPO® technology.